Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) EBIAT (2019 - 2023)

Historic EBIAT for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to -$46.7 million.

  • ADC Therapeutics' EBIAT rose 767.07% to -$46.7 million in Q3 2023 from the same period last year, while for Sep 2023 it was $3.8 billion, marking a year-over-year decrease of 1335.78%. This contributed to the annual value of $4.7 billion for FY2022, which is 234000.66% up from last year.
  • ADC Therapeutics' EBIAT amounted to -$46.7 million in Q3 2023, which was up 767.07% from -$48.9 million recorded in Q2 2023.
  • ADC Therapeutics' EBIAT's 5-year high stood at $4.7 billion during Q1 2022, with a 5-year trough of -$212.0 million in Q4 2021.
  • Its 5-year average for EBIAT is $472.2 million, with a median of -$20.3 million in 2020.
  • Within the past 5 years, the most significant YoY rise in ADC Therapeutics' EBIAT was 931652.73% (2022), while the steepest drop was 269695798.07% (2022).
  • ADC Therapeutics' EBIAT (Quarter) stood at -$35285.0 in 2019, then crashed by 57510.88% to -$20.3 million in 2020, then plummeted by 942.94% to -$212.0 million in 2021, then soared by 99.99% to -$24157.0 in 2022, then crashed by 193326.34% to -$46.7 million in 2023.
  • Its EBIAT stands at -$46.7 million for Q3 2023, versus -$48.9 million for Q2 2023 and $3.9 billion for Q1 2023.